Speaker

Prof. Wu has dedicated nearly 20 years to research and teaching in health economics and pharmacoeconomics. Her expertise spans health policy evaluation, pharmacoeconomic evaluation, real-world data analysis, and health-related quality of life and health utility study. She earned her PhD in Pharmacoeconomics through a joint program between Shenyang Pharmaceutical University and Peking University in 2007 and was a visiting scholar at the Schaeffer Center for Health Policy and Economics at the University of Southern California in 2013. Prof. Wu has authored over 100 high-impact scientific articles, led three National Natural Science Foundation of China projects, contributed to multiple pharmacoeconomics textbooks, and spearheaded the development of the China Guidelines for Pharmacoeconomic Evaluations (2020) and the Companion Guide to the China Guidelines for Pharmacoeconomic Evaluations (2022), promoting the development and standardization of pharmacoeconomics in China. She currently serves as Chair of the Pharmacoeconomics Committee of the Chinese Pharmaceutical Society, Vice Chair of the Pharmacoeconomics Committee of the China Health Insurance Research Association, Vice Chair of the Pharmacoeconomics Committee of the Chinese Society of Research Hospitals. She co-chaired the ISPOR Asia-Pacific Conferences in 2018 and 2022, served as Executive Chair of the 10th Huaxia Pharmacoeconomics and HTA Forum in 2019, and founded the China Young Scholars Forum on Pharmacoeconomics in 2017—organizing around 40 high-level academic meetings to date. As a national-level advisor, she provides strategic guidance to China’s National Healthcare Security Administration, playing a key role in reimbursement policy and healthcare-system reform.